Skip to content

San Bernardino Sun

70°F
Friday, March 27th 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ:EVO)

2.440 -0.020 (-0.81%)
Streaming Delayed Price Updated: 12:56 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 5 Next >
News headline image
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Via ACCESS Newswire
News headline image
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Via ACCESS Newswire
News headline image
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Via ACCESS Newswire
News headline image
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Via ACCESS Newswire
News headline image
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
Via ACCESS Newswire
News headline image
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Via ACCESS Newswire
News headline image
Evotec Announces Change in Management Board
Via ACCESS Newswire
News headline image
Evotec Announces Change in Management Board
Via ACCESSWIRE
News headline image
Comment on Withdrawn Non-Binding Offer
Via ACCESSWIRE
News headline image
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Via ACCESS Newswire
News headline image
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Via ACCESS Newswire
News headline image
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Via ACCESS Newswire
News headline image
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Via ACCESS Newswire
News headline image
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
Via ACCESS Newswire
News headline image
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Via ACCESS Newswire
News headline image
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Via ACCESS Newswire
News headline image
Evotec SE to announce first half-year results 2025 on 13 August 2025
Via ACCESS Newswire
News headline image
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
Via ACCESS Newswire
News headline image
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Via ACCESS Newswire
News headline image
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Via ACCESS Newswire
News headline image
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
Via ACCESS Newswire
News headline image
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Via ACCESS Newswire
News headline image
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Via ACCESS Newswire
News headline image
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Via ACCESS Newswire
News headline image
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
Via ACCESS Newswire
News headline image
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Via ACCESS Newswire
News headline image
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Via ACCESS Newswire
News headline image
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
Via ACCESS Newswire
News headline image
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
Via ACCESS Newswire
News headline image
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.